Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (22633)	6/23/1998 3:13:00 PM
From: Henry Niman	Respond to of 32384

Bernie, I keep on posting, but the street STILL doesn't get it. They will sooner or later and with the NASDAQ stabilizing, the street won't be able to keep ignoring the good news that keeps on coming. Maybe the Science paper will deliver the wake up call.

To: Flagrante Delictu who wrote (22633)	6/24/1998 7:19:00 AM
From: Henry Niman	Respond to of 32384

Speaking of designer estrogens, androgens, and progestins, a recent study suggests that estrogen may play a role in the battle against malignant melanoma: paradise-web.com

To: Flagrante Delictu who wrote (22633)	6/24/1998 8:26:00 AM
From: Henry Niman	Respond to of 32384

Here's the abstract describing anti-androgen stimulation of prostate cells: Vol. 95, Issue 13, 7379-7384, June 23, 1998 Biochemistry Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells Hiroshi Miyamoto, Shuyuan Yeh, George Wilding<Picture: dagger >, and Chawnshang Chang,<Picture: dagger >,<Picture: Dagger > ÿGeorge Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Biochemistry, University of Rochester Medical Center, Rochester, NY 14642; and <Picture: dagger >ÿUniversity of Wisconsin Comprehensive Cancer Center, Madison, WI 53792 Communicated by Jack Gorski, University of Wisconsin-Madison, Madison, WI, April 15,ÿ1998 (received for review January 9,ÿ1998) Although hormone therapy with antiandrogens has been widely used for the treatment of prostate cancer, some antiandrogens may act as androgen receptor (AR) agonists that may result in antiandrogen withdrawal syndrome. The molecular mechanism of this agonist response, however, remains unclear. Using mammalian two-hybrid assay, we report that antiandrogens, hydroxyflutamide, bicalutamide (casodex), cyproterone acetate, and RU58841, and other compounds such as genistein and RU486, can promote the interaction between AR and its coactivator, ARA70, in a dose-dependent manner. The chloramphenicol acetyltransferase assay further demonstrates that these antiandrogens and related compounds significantly enhance the AR transcriptional activity by cotransfection of AR and ARA70 in a 1:3 ratio into human prostate cancer DU145 cells. Our results suggest that the agonist activity of antiandrogens might occur with the proper interaction of AR and ARA70 in DU145 cells. These findings may provide a good model to develop better antiandrogens without agonist activity. ------------------------------------------------------------------------ <Picture: Dagger >ÿÿ To whom reprint requests should be addressed at: University of Rochester Medical Center, 601ÿElmwood Avenue, Box 626,ÿRochester, NY 14642.ÿe-mail: chang@pathology.rochester.edu.